A-MUPS score to differentiate patients with somatic symptom disorder from those with medical disease for complaints of non-acute pain

Shingo Suzuki
Yoshiyuki Ohira
Kazutaka Noda
Masatomi Ikusaka

Department of General Medicine,
Chiba University Hospital, Chiba,
Japan

Purpose: To develop a clinical score to discriminate patients with somatic symptom disorder (SSD) from those with medical disease (MD) for complaints of non-acute pain.

Methods: We retrospectively examined the clinical records of consecutive patients with pain for a duration of ≥ 1 month in our department from April 2003 to March 2015. We divided the subjects according to the diagnoses of definite SSD (as diagnosed and tracked by psychiatrists in our hospital), probable SSD (without evaluation by psychiatrists in our hospital), matched MD (randomly matched two patients by age, sex, and pain location for each definite SSD patient), unmatched MD, other mental disease, or functional somatic syndrome (FSS). We investigated eight clinical factors for definite SSD and matched MD, and developed a diagnostic score to identify SSD. We subsequently validated the model with cases of probable SSD and unmatched MD.

Results: The number of patients with definite SSD, probable SSD, matched MD, unmatched MD, other mental disease, and FSS was 104 (3.5%), 214 (7.3%), 197 (6.7%), 742 (25%), 708 (24%), and 978 (33%), respectively. In a conditional logistic regression analysis, the following five factors were included as independent predictors of SSD: Analgesics ineffective, Mental disorder history, Unclear provocative/palliative factors, Persistence without cessation, and Stress feelings/episodes (A-MUPS). The area under the receiver operating characteristic curve (AUC) of the model was 0.900 (95% CI: 0.864–0.937, $p < 0.001$), and the McFadden's pseudo- R -squared was 0.709. For internal validation, the AUC between probable SSD and unmatched MD was 0.930 (95% CI: 0.910–0.950, $p < 0.001$). The prevalence and the likelihood ratio of SSD increased as the score increased.

Conclusion: The A-MUPS score was useful for discriminating patients with SSD from those with MD for complaints of non-acute pain, although external validation and refinement should be needed.

Keywords: medically unexplained, somatoform, somatization, hypochondriasis, pain disorder, functional somatic syndrome

Introduction

Somatic symptom disorder (SSD) is conceptualized as a psychiatric disorder, which shows an excess degree of suffering beyond that resulting from the presence of somatic symptoms alone, as defined in the *Diagnostic and Statistical Manual of Mental Disorders* (DSM), Fifth Edition.¹ The diagnostic criteria consist of the following: one or more somatic symptoms that disrupt patients' daily life (criterion A); excessive thoughts, feelings, or behaviors related to their symptoms (criterion B); and a symptomatic state that typically persists for more than six months (criterion C).² SSD encompasses somatization disorder, undifferentiated somatoform disorder (SFD), pain disorder, and hypochondriasis (with somatic symptoms) of SFD as defined in DSM-IV,¹ although

Correspondence: Shingo Suzuki
Department of General Medicine, Chiba
University Hospital, 1-8-1, Inohana,
Chuo-ku, Chiba 260-8677, Chiba, Japan
Tel/Fax +81 43 224 4758
Email shngszkthk@yahoo.co.jp

excessive inclusion of patients is a concern,³ and can be diagnosed with or without the presence of medical disease (MD).² In this study, because these various names may be confusing, we use the term SSD to encompass all the terms that are included in the concept of SSD.

SSD is common because somatization accounts for 10% of primary care patients, which is the same prevalence as depression and anxiety.⁴ However, because SSD is one of the most difficult diseases to diagnose,⁵ doctors may order unnecessary diagnostic procedures to avoid overlooking MD.⁶ Such excessive interventions can foster somatic fixations of patients,⁷ leading to functional impairment, higher disability days, and increased health care costs.⁴ In addition, the early detection of mental illness is critical even for patients with somatic disease because mental treatments are recommended as soon as possible so as to prevent chronic state.⁸ Thus, there is a need to develop a comprehensive biopsychosocial approach that may be applied at an early stage.⁶

However, no gold standard diagnostic method has been established for SSD.⁹ Even the diagnostic criteria of the DSM-5 necessitate clinical experience when making assessments.¹⁰ Moreover, previous studies have used various terms for medically unexplained physical symptoms (MUPS), such as somatization, SFD, and functional somatic symptom,¹¹ and these various definitions and methods might have led to inconsistent conclusions.¹² Thus, SSD and its clinical features in particular have scarcely been studied.¹³

SSD patients may complain of various symptoms including pain, fatigue, and issues pertaining to gastrointestinal, cardiopulmonary, urogenital, neurological, skin and glands, or autonomic systems.¹⁴ Here, we studied patients with pain, which is common but of which it is challenging for doctors to determine the causes. Our objective was to develop a clinical score for discriminating patients with SSD from those with MD because physicians frequently are unable to identify the principal cause of pain between the two types of disorders, and worry about overlooking MD. We do not encourage mind–body dualism, and one reason for “excluding MD”, as abolished in the DSM-5, is related to limited reliability for determining patients’ symptoms as MUPS.² Accordingly, clinical features of SSD were compared to those of MD to develop our clinical score.

Methods

Study population

This was a retrospective cross-sectional study conducted at a university hospital in Japan. We investigated the medical records of consecutive patients who visited the Department

of General Medicine at Chiba University Hospital with pain from April 2003 to March 2015. We list the classification of patients in Figure 1. Because the purpose of this study was to investigate differences in clinical features between SSD and MD, we excluded patients complaining of acute pain, which doctors rarely consider as SSD. We defined acute pain as that with a duration of less than one month since onset because acute pain generally improves within several weeks.¹⁵ Patients were also excluded if their final diagnoses were undetermined or if we could not understand them in sufficient detail due to language problems, dementia, an uncooperative attitude, mental retardation, or deafness. Because the clinical features of mental disorders other than SSD, such as depression or anxiety, have been established and these disorders contribute independently to functional impairment,⁴ such disorders should be evaluated before considering whether a patient might be suffering from SSD in primary care settings. Therefore, patients with a chief diagnosis of a mental disorder other than SSD, including those comorbid with SSD, were also excluded.

Confirmation of diagnoses

Our department has a system whereby two or more physicians examine each patient, and spend sufficient time to evaluate biopsychosocial problems, because most patients visiting our department are referred with unknown diagnostics from primary or secondary medical institutions. If a diagnosis is inconsistent or unclear among the physicians, they consult another senior physician or specialist, or follow up until a final diagnosis is determined. Diagnoses of mental disorder were previously based on the DSM-IV and are currently based on the DSM-5, or by referral to psychiatrists in daily medical practice. When extracting the data for this study, two physicians independently checked the clinical records to determine the final diagnosis (thus, a total of four or more physicians confirmed each diagnosis), and the diagnoses of mental disorder, including SSD, were reconfirmed based on the DSM-5. If the final diagnosis was in doubt, further discussion took place with the physicians in charge of the patient. However, because there is no widely accepted method to diagnose SSD,⁹ reliability of the diagnosis is an important problem. We classified patients as having “definite SSD” for developing a diagnostic score based on confirmed diagnosis of SSD if two or more physicians and a psychiatrist in our hospital diagnosed SSD with no alteration of diagnosis after follow-up. Patients were classified as having “probable SSD” for validating the model if the diagnosis was by physicians without an evaluation by psychiatrists in our hospital, even if

Figure 1 Flowchart and classification of the patients.

Notes: *Including SSD if the primary diagnosis was another mental disorder. §Not combined with the diagnosis of SSD.

Abbreviations: SSD, somatic symptom disorder; FSS, functional somatic syndrome; MD, medical disease.

there existed a consistent diagnosis made by psychiatrists in other institutions. Although the concept of functional somatic syndrome (FSS) overlaps with SSD, patients with FSS who also meet SSD criteria have greater disability than those who do not,⁹ indicating that FSS can be regarded as a mild disorder compared to SSD. Thus, we classified patients as having “FSS” if they complained of nonspecific pain, as well as if they had a diagnosis of FSS, such as irritable bowel disease, non-ulcer dyspepsia, premenstrual syndrome, chronic pelvic pain, fibromyalgia, atypical or noncardiac chest pain, chronic fatigue syndrome, tension headache, temporomandibular joint dysfunction, or atypical facial pain,¹¹ when they did not meet the diagnostic criteria for SSD according to the DSM-5. Patients who met the criteria for both SSD and FSS were classified into the SSD group because most of such patients needed to be referred to psychiatrists, unlike cases of FSS

only. However, the clinical position of FSS is unclear,¹³ in terms of whether it should be categorized within SSD or strictly distinguished as non-SSD. Moreover, this study aimed to develop a clinical score to discriminate SSD from MD, and physicians who diagnose patients with FSS-related disease based on their diagnostic criteria but omit the diagnosis of SSD would not strengthen the patients’ somatic fixations because they are not concerned with MD; rather, they target functional improvement in such conditions. Therefore, we excluded FSS when developing our model, but investigated its nature in the validation phase.

Procedure

We randomly matched two patients with MD (defined as “matched MD”) by age (within two years), sex, and pain location (at least one part) for each definite SSD patient

to exclude biases related to these factors and to generate a versatile model because the diagnoses and clinical features of MD differ according to these factors. The pain locations were divided into eight: whole body (if patients used the term or if parts included all the upper and lower limbs, and trunk), head and neck, chest, abdomen, back, upper limb, lower limb, and genital area. We decided upon eight clinical factors to investigate via focus-group discussions in our department, based on past reports and clinical experiences: analgesics ineffective (we defined analgesics as only acetaminophen or nonsteroidal anti-inflammatory drugs [NSAIDs]), unclear provocative/palliative factors, persistence without cessation, progression, mental disorder history, stress feelings/episodes (prior to the onset or aggravation of pain), complaints other than pain, and duration of six or more months (from the onset of pain to the first visit to our department). Two physicians independently checked each clinical record to extract the data. When the data were inconsistent, this was resolved by discussion with a third physician. Although all factors were evaluated by interview sheet or medical record history, unclear provocative/palliative factors were also evaluated by physical examination.

In the validation, probable SSD patients and MD patients who were unmatched to definite SSD patients (defined as “unmatched MD”) were employed. All cases of SSD and all cases of MD were also employed because each SSD and MD group was not divided randomly, to prioritize confirming diagnoses of SSD in developing a model. To evaluate the nature of FSS, we assessed FSS + all SSD versus all MD, and all SSD versus FSS + all MD. Study approval was obtained from the institutional review board of the Graduate School of Medicine, Chiba University, without requirement of patient written consent because this study included no information

that can reveal the identity of a particular individual, thus ensuring confidentiality of patient data.

Statistical analysis

In the derivation, the factor of analgesics ineffective was evaluated according to 11 grades of improvement (0 [no effect] to 10 [temporarily complete disappearance of pain]). Missing data for this factor were substituted by the mean value of the two groups. We subsequently decided a binary cut-off value via the area under the receiver operating characteristic curve (AUC). Subsequently, the eight clinical factors of relevance to definite SSD and matched MD were evaluated by univariate analyses. The factors with a *P*-value of less than 0.15 in the univariate analyses were included in a conditional logistic regression model with forced entry method to identify the significant predictors ($p < 0.05$). The description utility of the model was evaluated by AUC, and the goodness of fit of the model was assessed using McFadden's pseudo-*R*-squared.

In the internal validation, the discrimination ability was assessed via AUC. The calibration was assessed by comparing the prevalence and the likelihood ratio of SSD according to the risk score. We regarded missing data for each factor as negative. We used StatsDirect version 3 (StatsDirect Ltd., Altricham, UK) for calculating the odds ratios for univariate analyses and SPSS Statistics for Windows version 22 (IBM Corp., Armonk, NY, USA) for other statistical analyses.

Results

Characteristics of the participants

We show age, sex, and pain locations for each group in Table 1 and the final diagnoses of MD according to pain location in the Supplementary material. There were 104 cases of definite SSD and 197 cases of matched MD (Figure 1).

Table 1 Age, gender, and pain location in each group

Basic information	Derivation			Validation			
	Definite SSD, n=104	Matched MD, n=197	<i>p</i> -value	Probable SSD, n=214	Unmatched MD, n=742	FSS, n=978	<i>p</i> -value
Age	52.0 (16.6)	52.1 (16.4)	0.97	47.3 (16.5)	54.2 (18.0)	48.7 (18.1)	<0.001
Male	42 (40%)	79 (40%)	0.96	69 (32%)	345 (46%)	437 (45%)	0.009
Location*							
Whole body	16 (15%)	28 (14%)	0.78	57 (27%)	41 (6%)	39 (4%)	<0.001
Head, neck	35 (34%)	46 (23%)	0.055	53 (25%)	120 (16%)	297 (30%)	<0.001
Chest	20 (19%)	30 (15%)	0.38	15 (7%)	106 (14%)	154 (16%)	0.004
Abdomen	29 (28%)	51 (26%)	0.71	46 (21%)	131 (18%)	319 (33%)	<0.001
Back	21 (20%)	38 (19%)	0.85	42 (20%)	97 (13%)	184 (19%)	0.003
Upper limb	14 (13%)	22 (11%)	0.56	22 (10%)	155 (21%)	61 (6%)	<0.001
Lower limb	11 (11%)	30 (15%)	0.26	36 (17%)	229 (31%)	70 (7%)	<0.001
Genital area	4 (4%)	4 (2%)	0.45	6 (3%)	6 (1%)	24 (2%)	0.025

Notes: Data are mean (SD) or n (%). *Multiple locations could be chosen, except in the case of whole body, if patients suffered pain in multiple regions.

Abbreviations: SSD, somatic symptom disorder; MD, medical disease; FSS, functional somatic syndrome.

Definite SSD cases that matched only one MD patient due to the lack of a matching case meeting all conditions consisted of the following, listed by pain location: four whole body (18-, 39-, 59-, and 68-year-old females), one head and neck (55-year-old female), one chest (65-year-old female), one back (38-year-old male), one upper limb (23-year-old female), and three genital area (60-year-old female and 61- and 66-year-old males). The number of cases of probable SSD, unmatched MD, and FSS was 214, 742, and 978, respectively (Figure 1).

Derivation

Pain improvement according to 11 grades of analgesia was recorded in 59 (57%) cases of definite SSD and 82 (42%) cases of matched MD. Missing values were substituted with the mean value of 2.3, while effectiveness (including no record of concrete improvement grades), ineffectiveness, and missing data occurred in six (5.8%), 56 (54%), and 42 (40%)

cases of definite SSD and 79 (40%), 32 (16%), and 86 (44%) cases of matched MD, respectively. The cut-off score was determined to be between 0 and 1 or more (AUC=0.789; 95% CI: 0.714–0.863, $p<0.001$). All factors, except for progression, had a p -value of less than 0.15 in univariate analyses (Table 2). In the conditional logistic regression analysis with forced entry method, the following five factors were included as independent predictors of SSD ($p<0.05$) in decreasing order of odds ratios (Table 3): mental disorder history, unclear provocative/palliative factors, analgesics ineffective, stress feelings/episodes, and persistence without cessation. The AUC of the model was 0.900 (95% CI: 0.864–0.937, $p<0.001$; Figure 2), and the McFadden's pseudo- R -squared was 0.709.

Validation

We show the results of five factors for probable SSD, unmatched MD, and FSS in Table 4. AUC was 0.930 (95% CI: 0.910–0.950, $p<0.001$) for probable SSD versus unmatched

Table 2 Univariate analysis of the eight factors between definite SSD and matched MD

Factors	Definite SSD, n=104	Matched MD, n=197	Odds ratio	95% CI	p-value
Analgesics*					
Effective	48 (46%)	165 (84%)	Ref		
Ineffective	56 (54%)	32 (16%)	6.02	3.39–10.7	<0.001
Missing data	0 (0%)	0 (0%)	NA	NA	NA
Provocative/palliative factors					
Clear	33 (32%)	153 (78%)	Ref		
Unclear	71 (68%)	43 (22%)	7.66	4.34–13.5	<0.001
Missing data	0 (0%)	1 (<1%)	NA	NA	NA
Persistence					
With cessation	30 (29%)	131 (66%)	Ref		
Without cessation	73 (70%)	63 (32%)	5.06	2.02–8.84	<0.001
Missing data	1 (1%)	3 (2%)	1.46	0.03–18.8	0.57
Progression					
Progressing	36 (35%)	55 (28%)	Ref		
Nonprogressing	64 (62%)	140 (71%)	0.70	0.41–1.21	0.18
Missing data	4 (4%)	2 (1%)	3.06	0.41–35.0	0.23
Mental disorder history					
Existent	20 (19%)	9 (5%)	4.91	2.02–12.7	<0.001
Nonexistent	81 (78%)	179 (91%)	Ref		
Missing data	3 (3%)	9 (5%)	0.74	0.13–3.06	0.76
Stress feelings/episodes					
Existent	55 (53%)	33 (17%)	5.67	3.13–10.3	<0.001
Nonexistent	40 (38%)	136 (69%)	Ref		
Missing data	9 (9%)	28 (14%)	1.09	0.42–2.63	0.83
Complaints other than pain					
Existent	58 (56%)	64 (32%)	2.62	1.56–4.40	<0.001
Nonexistent	46 (44%)	133 (68%)	Ref		
Missing data	0 (0%)	0 (0%)	NA	NA	NA
Duration					
Six or more months	71 (68%)	107 (54%)	1.87	1.10–3.20	0.019
Under six months	32 (31%)	90 (46%)	Ref		
Missing data	1 (1%)	0 (0%)	NA	NA	NA

Note: *Missing data were substituted by the mean value of the two groups.

Abbreviations: SSD, somatic symptom disorder; MD, medical disease; Ref, reference; NA, not applicable.

Table 3 Conditional logistic regression analysis of the factors with $p < 0.15$ in univariate analysis

Factors	Regression β coefficient	Odds ratio	95% CI	p-value
Mental disorder history	2.64	14.1	3.49–56.6	<0.001
Unclear provocative/palliative factor	2.32	10.2	3.71–28.1	<0.001
Analgesics ineffective	2.28	9.73	3.44–27.4	<0.001
Stress feelings/episodes	2.12	8.29	2.69–25.5	<0.001
Persistence without cessation	1.90	6.69	2.25–19.9	0.001
Complaints other than pain	0.85	2.35	0.91–6.06	0.078
Duration of six or more months	0.65	1.92	0.83–4.44	0.13

Figure 2 Receiver operating characteristic curves according to the five scores in derivation and validation phases.
Abbreviations: SSD, somatic symptom disorder; MD, medical disease; FSS, functional somatic syndrome.

MD, 0.932 (95% CI: 0.916–0.949, $p < 0.001$) for all SSD versus all MD, 0.730 (95% CI: 0.710–0.751, $p < 0.001$) for all SSD + FSS versus all MD, and 0.881 (95% CI: 0.862–0.901, $p < 0.001$) for all SSD versus all MD + FSS (Figure 2). The prevalence and the likelihood ratio of SSD increased as the score increased (Figures 3–6). When we defined the cut-off score as between 1 and 2, corresponding to the largest sum of sensitivity and specificity, the score of the five factors had a sensitivity of 0.916 and a specificity of 0.849 for probable SSD versus unmatched MD, 0.906 and 0.852 for all SSD versus all MD, 0.543 and 0.852 for all SSD + FSS versus all MD, and 0.906 and 0.710 for all SSD versus all MD + FSS, respectively.

Discussion

This is the first study to reveal the clinical features of SSD compared to MD, and to suggest a diagnostic score for non-acute pain. The following five factors composed the score:

Analgesics ineffective, Mental disorder history, Unclear provocative/palliative factors, Persistence without cessation, and Stress feelings/episodes (A-MUPS). Based on the discrimination ability of the A-MUPS score according to AUC (Figure 2) and the stratified prevalence and likelihood ratio of SSD in the validation (Figures 3–6), the clinical features of FSS are more similar to those of MD than those of SSD. This indicates that the A-MUPS score reflects specific clinical features of SSD defined in the DSM-5, that it would be possible to assess whether patients with FSS had a diagnosis combined with SSD or not, and that the concept of SSD should be separated from that of FSS.

Factor “A” of the A-MUPS score was Analgesics ineffective. Acetaminophen and NSAIDs are recommended in the initial treatment for cancer and non-cancer pain.¹⁵ Besides pharmacological mechanisms, placebo analgesia, to which endogenous opioids and dopamine contribute, influences analgesic effects.¹⁶ Positive expectancies strengthen the

degree of the placebo effect, while negative expectancies decrease the placebo effect, increase side effects, and induce nocebo effects.¹⁷ Although SSD patients visit multiple doctors as they seek care, the purpose of their behavior tends to be to persuade others that they are ill, so as to obtain

illness-related privileges.¹³ These properties may contribute to the ineffectiveness of analgesics.

Factor “M” was Mental disorder history. The comorbidity of SSD with depression and/or anxiety is high, with a rate of 26%–59%,¹⁸ and patients with mental disorder tend to develop SSD.¹⁹ In a study of anxiety disorder, the proportion of cases with SSD that followed anxiety versus anxiety that followed SSD was the same, and simultaneous onset of these disorders was rare.²⁰ Mental disorders influence each other.

Factor “U” was Unclear provocative/palliative factors. SSD patients complain of vague, imprecise, and changeable physical symptoms.²¹ Diagnostic criteria for SSD in the DSM-5 include “excessive thoughts, feelings, or behaviors related to somatic symptoms (criterion B)”;² functional, cortical issues would evoke or strengthen such symptoms. It is likely that no or minimal pain signal arises from the somatic organs, and thus, provocative/palliative factors cannot be clear.

Factor “P” was Persistence without cessation. Diagnostic criteria for SSD in the DSM-5 include persistence of symptoms.² Although somatic symptoms need not be continuous,²² our study showed that the possibility of SSD increased if pain continued without cessation. Because SSD patients have a tendency of selective attention to physical symptoms,¹⁸ unceasing consciousness of their pain would be causative.

Table 4 The five factors for probable SSD, unmatched MD, and FSS in the validation phase

Factors	Probable SSD, n=214	Unmatched MD, n=742	FSS, n=978
Analgesics			
Effective	25 (12%)	264 (36%)	188 (19%)
Ineffective	106 (50%)	99 (13%)	151 (15%)
Missing data	83 (39%)	379 (51%)	639 (65%)
Provocative/palliative factors			
Clear	41 (19%)	593 (80%)	520 (53%)
Unclear	171 (80%)	145 (20%)	445 (46%)
Missing data	2 (<1%)	4 (<1%)	13 (1%)
Persistence			
With cessation	56 (26%)	493 (66%)	699 (71%)
Without cessation	157 (73%)	240 (32%)	264 (27%)
Missing data	1 (<1%)	9 (1%)	15 (2%)
Mental disorder history			
Existent	68 (32%)	45 (6%)	111 (11%)
Nonexistent	141 (66%)	671 (90%)	812 (83%)
Missing data	5 (2%)	26 (4%)	54 (6%)
Stress feelings/episodes			
Existent	113 (53%)	58 (8%)	364 (37%)
Nonexistent	93 (43%)	544 (73%)	490 (50%)
Missing data	8 (4%)	130 (18%)	124 (13%)

Abbreviations: SSD, somatic symptom disorder; MD, medical disease; FSS, functional somatic syndrome.

Figure 3 Prevalence and likelihood ratio of SSD in validation phase (probable SSD versus unmatched MD).

Abbreviations: A-MUPS, Analgesics ineffective, Mental disorder history, Unclear provocative/palliative factors, Persistence without cessation, and Stress feelings/episodes; SSD, somatic symptom disorder; MD, medical disease; NA, not applicable.

Figure 4 Prevalence and likelihood ratio of SSD in validation phase (all SSD versus all MD).

Abbreviations: A-MUPS, Analgesics ineffective, Mental disorder history, Unclear provocative/palliative factors, Persistence without cessation, and Stress feelings/episodes; SSD, somatic symptom disorder; MD, medical disease; NA, not applicable.

Figure 5 Prevalence and likelihood ratio of SSD + FSS in validation phase (all SSD + FSS versus all MD).

Abbreviations: A-MUPS, Analgesics ineffective, Mental disorder history, Unclear provocative/palliative factors, Persistence without cessation, and Stress feelings/episodes; SSD, somatic symptom disorder; FSS, functional somatic syndrome; MD, medical disease; NA, not applicable.

Figure 6 Prevalence and likelihood ratio of SSD in validation phase (all SSD versus all MD + FSS).

Abbreviations: A-MUPS, Analgesics ineffective, Mental disorder history, Unclear provocative/palliative factors, Persistence without cessation, and Stress feelings/episodes; SSD, somatic symptom disorder; MD, medical disease; FSS, functional somatic syndrome.

Factor “S” was stress feelings/episodes. Mental pain share a common neuroanatomical pathway with physical pain; the anterior cingulate cortex is related to the experience of pain distress, and the right ventral prefrontal cortex is related to the regulation of pain distress.²³ Thus, cortical processing and interpretation of somatic signals depend on psychological salience,²⁴ so that cognition, mood, and context influence pain perception.²⁵ As SSD patients are more susceptible to pain than healthy individuals who are experiencing transient negative affect,²⁶ the former are readily affected by stress.

SSD patients often complain of multiple symptoms,¹⁴ but pain tends to be the sole severe complaint.² Although this is a reason why the factor “complaints other than pain” was not included in the model, some MD patients had objectively and easily identifiable complaints, including fever, swelling, and pallor. If we considered the quality of complaints, the factor may become of utility. Although the typical duration of symptoms is usually considered as more than six months, the factor “duration of six or more months” was also not included in the model. This suggests that SSD can be detected at an early stage, via other clinical features assessed by A-MUPS. Progression of pain generally indicates severe MD, while SSD patients attempt to convince others of their severe symptoms claiming aggravation.²⁷ Thus, it is difficult to distinguish SSD from MD via the time course of pain.

Strengths and limitations of this study

A strength of this study is its utilization of consecutive patients, most of whom were referred with unknown diagnostics. In addition, diagnoses were confirmed by two or more physicians who spent sufficient time to reach a satisfactory diagnosis, and diagnoses were also independently checked by another two physicians to minimize misdiagnosis. Moreover, we used the definite SSD data, which incorporated diagnosis by psychiatrists in our hospital with follow-up, to formulate our model. Although the results of the validation suggest the model is useful, these methods might have led to sampling bias.

Our study has several limitations. The possibility of sampling bias should be noted because the setting of this study was a single university hospital in Japan. Although our diagnoses of mental disorder including SSD were reconfirmed based on DSM-5 criteria by two or more independent physicians, they relied on medical records but not the medical practice itself. In addition, this was a retrospective cross-sectional study, although we tried to prevent recall bias and observer bias by double independent evaluations of medical records. Considering these limitations, we need to obtain prospective external validations in other multicenter settings. Mean-value substitution was used to replace missing data for the factor “analgesics ineffective” while generating the

model because the proportion of missing data was high due to no prior prescription, absence of history, or the restricted definition of analgesics as those initially recommended (i.e., acetaminophen and NSAIDs).¹⁵ However, in the model formulation, the proportions of effectiveness (including no record of concrete improvement grades), ineffectiveness, and missing data were 5.8%, 54%, and 40% in definite SSD, and 40%, 16%, and 44% in matched MD, respectively, which shows a similar proportion of missing data but clearly greater ineffectiveness in definite SSD. Namely, substitution of missing data narrowed the difference between the two groups, but a significant difference was observed so that we consider this factor as a characteristic of SSD. Finally, because responses of SSD patients may change on a daily basis, such patients should receive repeated evaluations.

Conclusion

This is the first study to develop a clinical diagnostic score (A-MUPS score) that differentiates patients with SSD from those with MD for complaints of non-acute pain. We expect the model will help to diagnose patients with SSD in consort with other validations. Further studies are needed to investigate the clinical features of SSD other than complaints of pain, the distinction between SSD and FSS, and the clinical differences among SSD, FSS, and other mental disorder.

Acknowledgment

The authors would like to thank Editage for the English language editing.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Dimsdale JE, Creed F, Escobar J, et al. Somatic symptom disorder: an important change in DSM. *J Psychosom Res.* 2013;75:223–228.
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
3. Frances A. The new somatic symptom disorder in DSM-5 risks mislabeling many people as mentally ill. *BMJ.* 2013;346:f1580.
4. Lowe B, Spitzer RL, Williams JB, Mussell M, Schellberg D, Kroenke K. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. *Gen Hosp Psychiatry.* 2008;30:191–199.
5. Dimsdale JE, Dantzer R. A biological substrate for somatoform disorders: importance of pathophysiology. *Psychosom Med.* 2007;69(9):850–854.
6. Bensing JM, Verhaak PF. Somatisation: a joint responsibility of doctor and patient. *Lancet.* 2006;367:452–454.
7. Biderman A, Yeheskel A, Herman J. Somatic fixation: the harm of healing. *Soc Sci Med.* 2003;56:1135–1138.
8. Freidl M, Spitzl SP, Prause W, et al. The stigma of mental illness: anticipation and attitudes among patients with epileptic, dissociative or somatoform pain disorder. *Int Rev Psychiatry.* 2007;19:123–129.
9. Häuser W, Bialas P, Welsch K, Wolfe F. Construct validity and clinical utility of current research criteria of DSM-5 somatic symptom disorder diagnosis in patients with fibromyalgia syndrome. *J Psychosom Res.* 2015;78(6):546–552.
10. Dimsdale JE, Levenson J. Diagnosis of somatic symptom disorder requires clinical judgment. *J Psychosom Res.* 2013;75(6):588.
11. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? *Lancet.* 1999;354:936–939.
12. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. *N Engl J Med.* 1999;341(18):1329–1335.
13. Noyes R Jr, Stuart SP, Watson DB. A reconceptualization of the somatoform disorders. *Psychosomatics.* 2008;49(1):14–22.
14. Fink P, Steen Hansen M, Sondergaard L. Somatoform disorders among first-time referrals to a neurology service. *Psychosomatics.* 2005;46(6):540–548.
15. Kapur BM, Lala PK, Shaw JL. Pharmacogenetics of chronic pain management. *Clin Biochem.* 2014; 47(13–14):1169–1187.
16. Colloca L, Klinger R, Flor H, Bingel U. Placebo analgesia: psychological and neurobiological mechanisms. *Pain.* 2013;154(4):511–514.
17. Klinger R, Colloca L, Bingel U, Flor H. Placebo analgesia: clinical applications. *Pain.* 2014;155(6):1055–1058.
18. Lowe B, Mundt C, Herzog W, et al. Validity of current somatoform disorder diagnoses: perspectives for classification in DSM-V and ICD-11. *Psychopathology.* 2008;41(1):4–9.
19. Lieb R, Zimmermann P, Friis RH, Høfler M, Tholen S, Wittchen HU. The natural course of DSM-IV somatoform disorders and syndromes among adolescents and young adults: a prospective-longitudinal community study. *Eur Psychiatry.* 2002;17(6):321–331.
20. Lieb R, Meinischmidt G, Araya R. Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: an update. *Psychosom Med.* 2007;69(9):860–863.
21. Noyes R, Stuart S, Watson DB, Langbehn DR. Distinguishing between hypochondriasis and somatization disorder: a review of the existing literature. *Psychother Psychosom.* 2006;75(5):270–281.
22. Kurlansik SL, Maffei MS. Somatic symptom disorder. *Am Fam Physician.* 2016;93(1):49–54.
23. Eisenberger NI, Lieberman MD, Williams KD. Does rejection hurt? An fMRI study of social exclusion. *Science.* 2003;302(5643):290–292.
24. Sharpe M. Somatic symptoms: beyond ‘medically unexplained’. *Br J Psychiatry.* 2013;203(5):320–321.
25. Tracey I. Imaging pain. *Br J Anaesth.* 2008;101(1):32–39.
26. Yoshino A, Okamoto Y, Yoshimura S, et al. Distinctive neural responses to pain stimuli during induced sadness in patients with somatoform pain disorder: an fMRI study. *Neuroimage Clin.* 2013;2:782–789.
27. Barr WB. Differential diagnosis of psychological factors evoked by pain presentations. *Clin Neuropsychol.* 2013;27(1):17–29.

Supplementary material

Table S1 Final diagnoses of medical diseases according to pain location

Whole body		
Polymyalgia rheumatica	Spondyloarthritis	Myopathy
Rheumatoid arthritis	Psoriasis	Steroid
Systemic lupus erythematosus	Reactive arthritis	Alcohol
Behcet's disease	Undifferentiated	Viral infection
Granulomatous polyarteritis	Periodic paralysis	Parvo virus
ACTH deficiency	Muscle cramp	Neuropathy
Adrenal insufficiency	Lymphoproliferative disease	Diabetic
Osteomalacia	Rhabdomyolysis	
Head and neck		
Migraine	Malignancy	Trauma
Cluster headache	Brain	Epilepsy
Paroxysmal hemicrania	Maxillary sinus	Giant cell arteritis
Primary stabbing headache	Hypopharyngeal	Relapsing polychondritis
Trigeminal neuralgia	Metastasis	PFAPA syndrome
Primary headache associated with sexual activity	Dry eye	Kikuchi's disease
Occipital neuralgia	Glossitis	Crowned dens syndrome
Mental neuralgia	Viral infection	Carotidynia
Postherpetic neuralgia	HIV	Subacute thyroiditis
Zoster	Pheochromocytoma	Sinusitis
Sleep apnea syndrome	Spondyloarthritis	Scleritis
Medication overuse headache	Psoriasis	Dyskinesia
Meningitis carcinomatosa	Spondylosis	Parkinson's disease
Benign tumor	Lichen planus	Syringomyelia
Chest		
Angina pectoris	Eosinophilic gastritis	Viral infection
Aortic dissection	Intercostal neuralgia	HIV
Rupture of Valsalva sinus	Postherpetic neuralgia	Bornholm disease
Takayasu arteritis	Costochondritis	Mondor's disease
Systemic lupus erythematosus	Gastric ulcer	Drug-induced myalgia
SAPHO syndrome	Malignancy	Fracture
Amyloidosis	Metastasis	Osteomalacia
Familial Mediterranean fever	Lymphoma	Muscle cramp
Sarcoidosis	Multiple myeloma	Neuropathy
Spondyloarthritis	Lung	Diabetic
Reactive arthritis	Gastric	Subcutaneous abscess
Ankylosing spondylitis	Benign tumor	Pneumothorax
Undifferentiated		
Abdomen		
Gastric ulcer	Idiopathic orchialgia	Familial Mediterranean fever
Appendicitis	Mesenteric panniculitis	Amyloidosis
Diverticulitis	Retroperitoneal fibrosis	ACNES
Invagination	Malignancy	Cholinergic urticaria
Cholecystolithiasis	Gastric	Immunoglobulin A vasculitis
Chronic pancreatitis	Duodenum	Superior mesenteric artery syndrome
Ovulation pain	Small intestine	Angina intestinalis
Ileus	Colon	Discitis
Eosinophilic gastroenteritis	Biliary tract	Radiculopathy
Crohn's disease	Pancreas	Intercostal neuralgia
Constipation	Ovary	Chronic urticaria
Renal abscess	Uterine body	Slipping rib syndrome
Endometriosis	Kidney	Thrombophlebitis

(Continued)

Table S1 (Continued)

Abdomen		
Hernia	Malignant lymphoma	Pubic symphysis inflammation
Inguinal hernia	Spinal cord	Zoster
Abdominal incision	Metastasis	Trauma
Salpingitis	Sarcoidosis	Neuropathy
Pelvic inflammatory disease	Systemic lupus erythematosus	Diabetic
Back		
Spondylosis	Spinal canal stenosis	Chronic pancreatitis
Radiculopathy	Pneumothorax	Malignancy
Fracture	Drug-induced myalgia	Metastasis
Intercostal neuralgia	Tight filum terminale	Pancreas
Discitis	Osteomalacia	Multiple myeloma
Costochondritis	SAPHO syndrome	Malignant lymphoma
Postherpetic neuralgia	Spondyloarthritis	Lung
Bornholm disease	Reactive arthritis	Pleural mesothelioma
Viral infection	Ankylosing spondylitis	Gastric
Cytomegalovirus	Amyloidosis	Unknown primary
Myositis	Systemic lupus erythematosus	Neuropathy
Streptococcus	Polymyalgia rheumatica	Diabetic
Myopathy	Familial Mediterranean fever	Parkinson's disease
Steroid	Cholinergic urticaria	Gastric ulcer
Ossification of the ligamentum flavum		
Upper limb		
Rheumatoid arthritis	Frozen shoulder	Plexopathy
Palindromic rheumatism	Gout	Diabetic
Polymyalgia rheumatica	Pseudogout	Lateral epicondylitis
RS3PE	Trigger finger	CIDP
Mixed connective tissue disease	Painful arc	Complex regional pain syndrome
Antiphospholipid syndrome	Cubital tunnel syndrome	Angioedema with eosinophilia
Behcet's disease	Radiculopathy	Lymphadenitis
Dermatomyositis	Syringomyelia	Tuberculosis
Systemic lupus erythematosus	Ossification of posterior longitudinal ligament	Kikuchi's disease
Sjogren's syndrome	Myelopathy	Parkinson's disease
Scleroderma	Glomangioma	ACTH deficiency
Graves' disease	Wartenberg's syndrome	Hypopituitarism
Familial Mediterranean fever	Frostbite	Adrenal insufficiency
Spondyloarthritis	Drug-induced myalgia	Malignancy
Psoriasis	Rotator cuff tear	Lung (Pancoast tumor)
Inflammatory bowel disease	Myopathy	Malignant lymphoma
Reactive arthritis	Hypokalemia	Multiple myeloma
Undifferentiated	Viral infection	Myelodysplastic syndrome
Osteoarthritis	Parvo virus	Angina pectoris
Carpal tunnel syndrome	Cytomegalovirus	Raynaud syndrome
Calcific tendinitis	Neuropathy	Thoracic outlet syndrome
Tenosynovitis	Diabetic	Neuralgia
Lower limb		
Radiculopathy	Baker's cyst	Postherpetic neuralgia
Pubic symphysis inflammation	Femur head necrosis	Neuropathy
Spinal canal stenosis	Stasis dermatitis	Alcoholic
Metatarsalgia	Livedo reticularis	Diabetic
Epiphysiopathy	Angioedema with eosinophilia	Vitamin B1 deficiency
Tenosynovitis	Eosinophilic fasciitis	CIDP
Piriformis syndrome	Spondyloarthritis	Restless legs syndrome
Osteochondritis dissecans	Reactive arthritis	Complex regional pain syndrome
Varicosis	Psoriasis	Erythromegalia
Bursitis	Ankylosing spondylitis	ACTH deficiency
Myositis	Undifferentiated	Hypopituitarism
Streptococcus	Rheumatoid arthritis	Adrenal insufficiency

(Continued)

Table S1 (Continued)

Lower limb		
Myopathy	Palindromic rheumatism	Painless thyroiditis
Hypothyroid	Mixed connective tissue disease	Osteomalacia
Tarsal tunnel syndrome	Familial Mediterranean fever	Peripheral artery disease
Ossification of posterior longitudinal ligament	Dermatomyositis	Raynaud syndrome
Erythema nodosum	Polymyositis	Malignancy
Morton's disease	Focal myositis	Chondrosarcoma
Meniscus injury	Behcet's disease	Uterine cervix
Panniculitis	Systemic lupus erythematosus	Multiple myeloma
Viral infection	Immunoglobulin A vasculitis	Malignant lymphoma
Parvo virus	Cryoglobulinemia vasculitis	Metastasis
Cytomegalovirus	Polyarteritis nodosa	Benign tumor
Plantar fasciitis	Polymyalgia rheumatica	Myelodysplastic syndrome
Gout	RS3PE	Hernia
Pseudogout	Sjogren's syndrome	Obturator
Neuralgia	Graves' disease	Inguinal
Obturator	Muscle cramp	Lymphadenitis
Lateral femoral cutaneous nerve	Parkinson's disease	Frostbite
Genital area		
Malignancy	Hemorrhoid	Pudendal neuralgia
Bladder, ureter	Familial Mediterranean fever	Adhesive arachnoiditis
Cholinergic urticaria	Retroperitoneal fibrosis	

Abbreviations: ACTH, adrenocorticotrophic hormone; PFAPA, periodic fever, aphthous stomatitis, pharyngitis, and adenitis; SAPHO, synovitis, acne, pustulosis, hyperostosis, and osteitis; ACNES, abdominal cutaneous nerve entrapment syndrome; RS3PE, remitting seronegative symmetrical synovitis with pitting edema; CIDP, chronic inflammatory demyelinating polyneuropathy.

Journal of Pain Research

Publish your work in this journal

The Journal of Pain Research is an international, peer reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication.

Submit your manuscript here: <https://www.dovepress.com/journal-of-pain-research-journal>

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress